المؤلفون: Kollb-Sielecka M; European Medicines Agency (EMA), London, United Kingdom. Electronic address: marta.kollb-sielecka@ema.europa., Demolis P; European Medicines Agency (EMA), London, United Kingdom; National Agency for the Safety of Medicines and Health Products (ANSM), France., Emmerich J; European Medicines Agency (EMA), London, United Kingdom; National Agency for the Safety of Medicines and Health Products (ANSM), France., Markey G; European Medicines Agency (EMA), London, United Kingdom; Medicines and Healthcare Regulatory Agency (MHRA), London, United Kingdom., Salmonson T; European Medicines Agency (EMA), London, United Kingdom; Läkemedelsverket, Medical Products Agency, Uppsala, Sweden., Haas M; European Medicines Agency (EMA), London, United Kingdom.

المصدر: Sleep medicine [Sleep Med] 2017 May; Vol. 33, pp. 125-129. Date of Electronic Publication: 2017 Feb 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100898759 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-5506 (Electronic) Linking ISSN: 13899457 NLM ISO Abbreviation: Sleep Med Subsets: MEDLINE

مواضيع طبية MeSH: Narcolepsy/*drug therapy , Piperidines/*therapeutic use , Receptors, Histamine H3/*drug effects, Adolescent ; Adult ; Aged ; Animals ; Attention/drug effects ; Cataplexy/drug therapy ; Clinical Trials, Phase III as Topic ; Cognition/drug effects ; Drug Inverse Agonism ; Humans ; Middle Aged ; Piperidines/administration & dosage ; Piperidines/adverse effects ; Piperidines/metabolism ; Receptors, Histamine H3/physiology ; Treatment Outcome ; Wakefulness-Promoting Agents/pharmacology ; Young Adult